Form 4: Fate Therapeutics Director Shefali Agarwal Granted 55,000 Stock Options

Fate Therapeutics, Inc. has reported that Director Shefali Agarwal was granted 55,000 stock options with an exercise price of $1.32, as part of the company's non-employee director compensation policy.

Summary

• Shefali Agarwal, a Director of Fate Therapeutics, Inc. (FATE), was granted 55,000 stock options.
• The options have an exercise price of $1.32 per share.
• The transaction date for this grant was May 29, 2025.
• These options were granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy, which provides for annual equity grants to non-employee directors on the date of the Annual Meeting of Stockholders.
• The shares subject to this option will vest and become exercisable on the earlier of May 29, 2026, or the date of the Issuer's 2026 Annual Meeting of Stockholders.
• Vesting is contingent upon Ms. Agarwal's continued service on the Issuer's Board of Directors.
• The options have an expiration date of May 29, 2035.
• Following this transaction, Shefali Agarwal beneficially owns 55,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it indicates routine corporate governance and director alignment, with no negative surprises. The grant of options is a standard compensation practice.

Positives

• The grant of stock options aligns the interests of Director Shefali Agarwal with those of shareholders, as the value of the options is tied to the company's stock performance.
• This transaction is part of a standard, pre-established compensation policy for non-employee directors, indicating consistent corporate governance practices.

Negatives

• The issuance of new stock options, upon exercise, can lead to a slight dilution of existing shareholder equity, although the amount is relatively small in the context of a public company.

Risks

• The vesting of the granted options is subject to the reporting person's continued service on the Issuer's Board of Directors, meaning the options could be forfeited if service ceases before vesting.

Future Outlook

The granted stock options are set to vest on the earlier of May 29, 2026, or the date of the Issuer's 2026 Annual Meeting of Stockholders, contingent on the director's continued service.

Industry Context

This Form 4 filing reflects a routine compensation event for a director in a publicly traded biotechnology company. Equity grants are a common practice in the industry to attract and retain talent, particularly for non-employee directors, and to align their interests with long-term company performance.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is a standard practice across the biotechnology and pharmaceutical industries, comparable to compensation structures at companies like Gilead Sciences, Amgen, or Regeneron Pharmaceuticals, which often include equity components to incentivize long-term value creation.
• The vesting schedule, tied to continued service and an annual meeting, is typical for director equity awards, ensuring ongoing commitment to corporate governance and strategic oversight.

Corporate Governance

Related Party Transactions

• The grant of 55,000 stock options to Shefali Agarwal, a Director of Fate Therapeutics, Inc., constitutes a related party transaction as it involves compensation to a member of the company's board of directors.

Stakeholder Impact

• Shareholders: The grant of options, while aligning director interests, could lead to minor dilution upon exercise. However, it is a standard practice for director compensation.
• Employees: No direct impact mentioned, but consistent director compensation practices contribute to overall corporate stability and governance.

Next Steps

• The stock options will vest on the earlier of May 29, 2026, or the date of Fate Therapeutics' 2026 Annual Meeting of Stockholders, subject to continued service.
• The options will remain exercisable until their expiration date of May 29, 2035.

Key Dates

Keywords

Fate Therapeutics, FATE, SEC Form 4, Stock Options, Director Compensation, Equity Grant, Insider Transaction, Beneficial Ownership, Biotechnology, Pharmaceuticals